Last update Jan. 13, 2024

Para-aminosalicylic Acid (PAS)

Compatible

Safe product and/or breastfeeding is the best option.

Aminosalicylic acid (or 4-aminosalicylic acid) and its salts are antimycobacterials generally administered in association with isoniazid in the treatment of multidrug-resistant tuberculosis. The sodium salt is better tolerated than the free acid. Oral administration in two to three daily doses. It is also used, like 5-aminosalicylic acid or Mesalazine, in the treatment of ulcerative colitis rectally.

It is excreted in breast milk in clinically insignificant amounts (Holdiness 1984) and no problems have been observed in infants whose mothers have taken it. (Drobac 2005)

Expert authors consider it safe for use during lactation. (Arbex 2010).

 

Alternatives

We do not have alternatives for Para-aminosalicylic Acid (PAS) since it is relatively safe.

Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.

Jose Maria Paricio, Founder & President of APILAM/e-Lactancia

Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.

Thank you for helping to protect and promote breastfeeding.

José María Paricio, founder of e-lactancia.
DONATE NOW

Other names

Para-aminosalicylic Acid (PAS) is also known as


Para-aminosalicylic Acid (PAS) in other languages or writings:

Group

Para-aminosalicylic Acid (PAS) belongs to this group or family:

Tradenames

Main tradenames from several countries containing Para-aminosalicylic Acid (PAS) in its composition:

List of 12 tradenames

Pharmacokinetics

Variable Value Unit
Oral Bioavail. > 90 %
Molecular weight 153 daltons
Protein Binding 50 - 70 %
pKa 3.68 -
Tmax 1 - 4 hours
T½ 1 hours
M/P ratio 0.1 - 0.2 -
Theoretical Dose 0.15 mg/Kg/d
Relative Dose 0.1 %
Ped.Relat.Dose 0.01 - 0.1 %

References

  1. Arbex MA, Varella Mde C, Siqueira HR, Mello FA. Antituberculosis drugs: drug interactions, adverse effects, and use in special situations. Part 2: second line drugs. J Bras Pneumol. 2010 Sep-Oct;36(5):641-56. Abstract Full text (link to original source) Full text (in our servers)
  2. Drobac PC, del Castillo H, Sweetland A, Anca G, Joseph JK, Furin J, Shin S. Treatment of multidrug-resistant tuberculosis during pregnancy: long-term follow-up of 6 children with intrauterine exposure to second-line agents. Clin Infect Dis. 2005 Jun 1;40(11):1689-92. Epub 2005 Apr 18. Abstract Full text (link to original source) Full text (in our servers)
  3. Holdiness MR. Antituberculosis drugs and breast-feeding. Arch Intern Med. 1984 Abstract Full text (link to original source)

Total visits

9,764

Help us improve this entry

How to cite this entry

Do you need more information or did not found what you were looking for?

   Write us at elactancia.org@gmail.com

e-lactancia is a resource recommended by Amamanta of Spain

Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM